• Mashup Score: 2
    The future of HER2-directed therapies in non-small cell lung cancer - 14 day(s) ago

    Joshua Sabari, MD, New York University Langone Health, New York, NY, provides an overview of the growing options in the HER2 space for non-small cell lung cancer (NSCLC). Zongertinib stands out due to its clean side effect profile, with minimal toxicity, no risk of interstitial lung disease, and no significant gastrointestinal or dermatological side effects. The approval of trastuzumab deruxtecan will also provide patients with much needed options. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥 @JSabari of @nyulangone highlights promising HER2-targeted therapies in #NSCLC: 🌟Zongertinib shows minimal toxicity, while trastuzumab deruxtecan adds much-needed options for patients ➡️Watch: https://t.co/HZFoeiU5Vo @ASCO #ASCO25 #HER2 #LungCancer #LCSM #ImmunoOnc

  • Mashup Score: 1
    Utilizing midkines to improve outcomes in SCLC and MCC - 15 day(s) ago

    Curtis Perry, MD, PhD, Yale University, New Haven, CT, describes the benefits of identifying midkines in immune resistant Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) tumors, highlighting the possibility of improved patient outcomes through enhanced treatment strategies. Dr Perry emphasizes the importance of personalized medicine and the need for further research to fully understand the mechanisms underlying these cancers. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Curtis Perry, MD, PhD, of @Yale discusses the role of midkines in immune-resistant #MCC & #SCLC, pointing to potential for better outcomes with tailored strategies: ➡️ https://t.co/8IBoAE0O3p⬅️ @ASCO #ASCO25 #MCC #LungCancer #LCSM #ImmunoOnc #Skcsm

  • Mashup Score: 6
    Improving early clinical trial enrolment in pediatric oncology - 16 day(s) ago

    Lesleigh Abbott, MD, The Children’s Hospital of Eastern Ontario, Ottawa, Canada, gives an overview of barriers to early-phase clinical trial enrolment for pediatric patients with cancer. Limitations include the lack of availability of trials, exacerbated by Canada’s vast geography and limited trial locations. To address this, increasing the number of trials at multiple centers, providing support to patients and families to access trials at other centers, and potentially creating satellite models from main hubs to increase accessibility are suggested. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🌟Lesleigh Abbott, MD, outlines barriers to early-phase trial access for kids with cancer in Canada, including geographic limits & trial scarcity. Multi-center access & satellite hubs may help bridge the gap. 🎥 https://t.co/FD3pU6rLIs @ASCO #ASCO25 #Oncology

  • Mashup Score: 4
    Reforming the treatment landscape in melanoma with T-cell therapies - 16 day(s) ago

    Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, shares his insight into the emerging T-cell therapies for patients with melanoma and their impact on the treatment landscape. The potentially curative treatments are currently undergoing Phase III testing with results expected in the coming years that will transform the standard of care for patients with melanoma. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Martin Wermke, MD, of @tudresden_de highlights emerging T-cell therapies in melanoma, now in Phase III trials. These potentially curative approaches could reshape the standard of care: ➡️https://t.co/O7yRnUlr0b⬅️ @ASCO #ASCO25 #Skcsm #Melsm #ImmunOnc #CTSM

  • Mashup Score: 1
    Evaluating fianlimab and cemiplimab in PD-L1+ recurrent/metastatic HNSCC - 17 day(s) ago

    Danny Rischin, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, describes the design of a Phase II trial (NCT06769698) of fianlimab plus cemiplimab versus cemiplimab plus placebo in patients with recurrent or metastatic PD-L1 expressing head and neck squamous cell carcinoma (HNSCC). The study includes HPV-positive and HPV-negative cohorts, with the primary endpoint of objective response rate. Secondary endpoints include progression-free survival, disease control rate, and safety. This trial aims to explore dual checkpoint blockade as a potential strategy to enhance clinical outcomes. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      Danny Rischin, MD of @PeterMacCC details a Phase II trial of fianlimab + cemiplimab vs placebo in PD-L1+ recurrent/metastatic HNSCC, including both HPV+/- cohorts. Can dual checkpoint blockade improve outcomes? https://t.co/LMyuHYtyS4 @ASCO #ASCO25 #HNCsm #ImmunoOnc #CTSM

  • Mashup Score: 2
    Important considerations in developing CAR-T cell therapy for GBM - 17 day(s) ago

    Reena Thomas, MD, PhD, Stanford University, Stanford, CA, comments on the importance of managing on-target tumor-associated inflammatory neurologic impacts in patients with glioblastoma (GBM). The therapeutic potential of CAR T cell therapy needs to be balanced with the risk of neurologic sequelae, and it is important to understand the methodology of dosing parameters and patient care to mitigate these impacts. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Prof. Reena Thomas of @Stanford highlights the need to manage inflammatory neurologic effects in pts with GBM receiving CAR T therapy - balancing efficacy with safety through thoughtful dosing and care strategies: ➡️https://t.co/viQErVvEGQ⬅️ @ASCO #ASCO25 #BTSM #ImmunoOnc

  • Mashup Score: 1
    How will ctDNA and liquid biopsies be utilized in gynecological cancers? - 18 day(s) ago

    Jyoti Mayadev, MD, University of California San Diego Medical Center, San Diego, CA, discusses the emerging developments in liquid biopsies and circulating tumor DNA (ctDNA) in the management of gynecological cancers. Findings of the CALLA trial (NCT03830866), showed that ctDNA is an effective indicator of treatment response in patients with locally advanced cervical cancer. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Jyoti Mayadev, MD, of @UCSDHealth discusses how ctDNA is shaping the future of gynecologic cancer care. 🌟CALLA trial data shows ctDNA effectively tracks treatment response in locally advanced cervical cancer https://t.co/SsTxFJhC4h @ASCO #ASCO25 #GynOnc #CTSM #TrialUpdate

  • Mashup Score: 6
    Post-ASCO 2025 Breast Cancer Highlights Archives - VJOncology - 20 day(s) ago

    We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      LAST CHANCE to register for our #BreastCancer Post-#ASCO2025 highlights webinar taking place TOMORROW🚨 💻 The #BreastCancer session will be charied by @evaciruelos & moderated by Prof. Lisa Carey, @lab_kok AGENDA 👉 https://t.co/0FNKfXU9R8 REGISTER 👉 https://t.co/OVSDOKZdss https://t.co/HReWyZzCML

Load More